News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Dynavax Technologies Corporation Appoints Francis R. Cano, Ph.D. to Board of Directors
November 5, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BERKELEY, Calif.--(BUSINESS WIRE)--Dynavax Technologies Corporation (Nasdaq:DVAX) announced today that Francis R. Cano, Ph.D. has been appointed to Dynavax’s Board of Directors effective November 3, 2009.
Twitter
LinkedIn
Facebook
Email
Print
People
Dynavax Technologies
MORE ON THIS TOPIC
Funding
Sling catches $123M series C for thyroid eye disease pill
September 16, 2026
·
2 min read
·
Tristan Manalac
FDA
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
September 16, 2026
·
1 min read
·
Jef Akst
Deals
GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
September 15, 2026
·
2 min read
·
Gabrielle Masson
Layoffs
GSK lays off 650 staffers amid closure of German vaccine manufacturing site
September 15, 2026
·
2 min read
·
Tristan Manalac